J&J Denied Injunction Over Private-Label Ustekinumab In US
Originator Appeals After Court Refuses To Block Samsung Bioepis And Sandoz
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
